Combining an existing small-molecule protein therapy called tumor necrosis factor related apoptosis-inducing ligand (TRAIL) ...

Combining an existing small-molecule protein therapy called tumor necrosis factor related apoptosis-inducing ligand ...

Combining an existing small-molecule protein therapy called tumor necrosis factor related apoptosis-inducing ligand with ...

Treatment with a cold atmospheric plasma reduced the recurrence rate of melanoma tumours after surgery by roughly 50% ...

New Jersey, USA-based Imunon announced new translational data from the Phase II OVATION 2 Study of IMNN-001, an ...

Researchers from Rice University and Vanderbilt University have made significant advancements in the fight against prostate ...

Results from OVATION 2 Study continue to validate TheraPlas® technology, demonstrating DNA-mediated production of key anti-cancer immune cytokines following treatment IMNN-001 continues to show ...

Anixa Biosciences receives approval of protocol amendment for ovarian cancer CAR-T clinical trial: San Jose, California Friday, February 21, 2025, 18:00 Hrs [IST] Anixa Bioscience ...

Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer today announced that it, along with its partner Moffitt ...

Rising air pollution, changes in hormone levels, immune system imbalances and longer life expectancy are increasing the risk of lung cancer in women who have never touched a cigarette.

Interdisciplinary collaboration is key to reducing the risk for osteonecrosis of the jaw and improving patient care.

A 96-week clinical trial found that 300 mg of Vitamin E significantly improved liver histology and reduced inflammation in ...